Allspring Global Investments
DSGN icon

Allspring Global Investments’s Design Therapeutics DSGN Stock Holding History

Allspring Global Investments’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-201
Closed -$2.06K – 2810
2022
Q4 		$2.06K Sell
201
-5
-2% -$68 ﹤0.01% 2847
2022
Q3 		$3K Buy
+206
New +$4.1K ﹤0.01% 2804

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Allspring Global Investments's DSGN Position: Q1 2023 in Review

Allspring Global Investments sold out of Design Therapeutics (DSGN) in Q1 2023, closing a stake of 201 shares — an estimated $2.06K sold.

Allspring Global Investments first reported a position in DSGN in Q3 2022 and held it in 2 quarters. The position peaked at $3K in Q3 2022. 96 funds tracked by Wall St. Rank hold DSGN as of Q1 2023.

  • Allspring Global Investments reported no remaining Design Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Allspring Global Investments sold 201 Design Therapeutics shares in Q1 2023, an estimated $2.06K.
  • Allspring Global Investments first reported a position in Design Therapeutics in Q3 2022 and held it in 2 quarters.
  • Allspring Global Investments's Design Therapeutics position peaked at $3K in Q3 2022.
  • 96 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2023.

Based on Allspring Global Investments's 13F filing for Q1 2023, filed 13 Apr 2023.